Because fluvastatin was the most effective inducer of KLF4 and DPYSL2A (Fig. 2C), we treated an additional non‐APL AML cell line (HL‐60) with fluvastatin, resulting in suppressed proliferation in a dose‐dependent manner (Fig. 3A). This evidence concerns the gene KLF4 and acute myeloid leukemia.